CEL-SCI Corporation To Present At The LD Micro Main Event

VIENNA, VA / ACCESSWIRE / November 30, 2015 / CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it will be presenting at the 8th annual LD Micro Main Event on Thursday, December 3rd at 11:00 am PT / 2:00 pm ET. Geert Kersten, Chief Executive Officer of CEL-SCI, will be giving the presentation and meeting with investors.

A live audio webcast of the presentation and replay will be available on CEL-SCI’s website at http://www.cel-sci.com/investor_relations.html. The replay of the presentation will be available for 90 days.

The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 210 companies in the small/micro-cap space.

About CEL-SCI Corporation

CEL-SCI’s work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is currently being studied in a pivotal Phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the head and neck. If the study endpoint, which is a 10% improvement in overall survival of the subjects treated with the Multikine treatment regimen plus the current standard of care (SOC) as compared to subjects treated with the current SOC only, is satisfied, the study results will be used to support applications that the Company plans to submit to regulatory agencies in order to seek commercial marketing approvals for Multikine in major markets around the world. Additional clinical indications for Multikine that are being investigated include the treatment of cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase 1 trial of the former indication has been completed at the University of Maryland. The latter indication is now in a Phase 1 trial in conjunction with the U.S. Naval Medical Center, San Diego, under a CRADA and University of California, San Francisco (UCSF).

CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology for the potential treatment of pandemic influenza in hospitalized patients and as a potential vaccine for the treatment of rheumatoid arthritis.

The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

About LD Micro

LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm also hosts the LD Micro Invitational in June. It is a non-registered investment advisor. For more information, please contact 408-457-1042 or visit www.ldmicro.com

8229 Boone Boulevard, Suite 802
Vienna, VA 22182. USA
Telephone (703) 506-9460
www.cel-sci.com

COMPANY CONTACT:

Gavin de Windt
CEL-SCI Corporation
(703) 506-9460

SOURCE: CEL-SCI via LD Micro

ReleaseID: 434032